LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 15

Search options

  1. Article ; Online: Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry.

    Viveiros Rosa, Sandro G / Santos, Wilson C

    Pharmaceutical patent analyst

    2022  Volume 11, Issue 2, Page(s) 57–73

    Abstract: By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency ... ...

    Abstract By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.
    MeSH term(s) Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Antiviral Agents/adverse effects ; COVID-19/drug therapy ; Humans ; SARS-CoV-2
    Chemical Substances Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
    Language English
    Publishing date 2022-05-31
    Publishing country England
    Document type Journal Article ; Meta-Analysis
    ISSN 2046-8962
    ISSN (online) 2046-8962
    DOI 10.4155/ppa-2021-0023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Vaccines and treatments for Zika virus infection: patent status, triumphs and challenges.

    Viveiros Rosa, Sandro G / Santos, Wilson C

    Pharmaceutical patent analyst

    2021  Volume 10, Issue 5, Page(s) 209–213

    MeSH term(s) Humans ; Vaccines ; Zika Virus ; Zika Virus Infection/prevention & control
    Chemical Substances Vaccines
    Language English
    Publishing date 2021-09-07
    Publishing country England
    Document type Editorial
    ISSN 2046-8962
    ISSN (online) 2046-8962
    DOI 10.4155/ppa-2021-0014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Patent profile for the approved and in clinical trials Mpox vaccines.

    der Weid, Irene von / de Souza Mendes, Cristina d'Urso / Fonseca, Paula C / Viveiros Rosa, Sandro G

    Pharmaceutical patent analyst

    2023  Volume 12, Issue 3, Page(s) 103–111

    Abstract: Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no ... ...

    Abstract Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.
    MeSH term(s) Humans ; Mpox (monkeypox) ; Vaccines ; Technology
    Chemical Substances Vaccines
    Language English
    Publishing date 2023-09-06
    Publishing country England
    Document type Journal Article
    ISSN 2046-8962
    ISSN (online) 2046-8962
    DOI 10.4155/ppa-2023-0017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: The race for clinical trials on Omicron-based COVID-19 vaccine candidates: Updates from global databases.

    Viveiros-Rosa, Sandro G / Mendes, Cristina Ds / Farfán-Cano, Galo G / El-Shazly, Mohamed

    Narra J

    2022  Volume 2, Issue 3, Page(s) e88

    Abstract: The coronavirus disease 2019 (COVID-19) has caused more than 6.5 million deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has the greatest transmission rate and can cause ... ...

    Abstract The coronavirus disease 2019 (COVID-19) has caused more than 6.5 million deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has the greatest transmission rate and can cause hospitalization in vaccinated individuals. It has been the most distinct SARS-CoV-2 variant of concern to date. The existing inactivated vaccines made with the wild-type strain are less efficient to prevent disease and/or hospitalization associated with the Omicron variant, even after a booster dose. Hence, it is crucial to develop new vaccines that are effective against this variant. The objective of this study was to summarize the data on existing clinical trials for new COVID-19 vaccines formulated against Omicron variant. Clinical trials from the international clinical trials registry platforms were searched and analyzed. As of June 10, 2022, a total of 15 clinical trials are available consisting of six and nine clinical trials of inactivated and messenger RNA (mRNA)-based vaccine candidates containing the Omicron variant, respectively. Those trials are evaluating four inactivated and four mRNA-based vaccine candidates. Although Omicron-specific vaccines are highly desired, their development is challenging since the SARS-CoV-2 variant formation is still unpredictable. Although two vaccines from Pfizer and Moderna have been approved for emergency use in the US and the UK for Omicron variant, the Asian pharmaceutical companies such as CNBG (Sinopharm), Sinovac, and Shifa Pharmed also have Phase 3 clinical trials under development and almost all clinical trials are expected to be completed in 2023. These results should help guide academics and policymakers in the COVID-19 vaccine field regarding investments in updated booster doses against the SARS-CoV-2 Omicron variant.
    Language English
    Publishing date 2022-11-06
    Publishing country Indonesia
    Document type Journal Article
    ISSN 2807-2618
    ISSN (online) 2807-2618
    DOI 10.52225/narra.v2i3.88
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Vector competence of

    Viveiros-Rosa, Sandro G / Regis, Eduardo G / Santos, Wilson C

    Revista panamericana de salud publica = Pan American journal of public health

    2020  Volume 44, Page(s) e7

    Abstract: Objective: To identify studies on the competence of : Methods: We performed an integrative review to identify relevant articles on specific experiments to determine whether : Results: We identified 344 studies, of which 36 were considered for this ...

    Abstract Objective: To identify studies on the competence of
    Methods: We performed an integrative review to identify relevant articles on specific experiments to determine whether
    Results: We identified 344 studies, of which 36 were considered for this review. In 8 studies, infection in salivary glands of
    Conclusions: There is still a lack of compelling evidence that indicates
    Language English
    Publishing date 2020-02-03
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1376934-0
    ISSN 1680-5348 ; 1020-4989
    ISSN (online) 1680-5348
    ISSN 1020-4989
    DOI 10.26633/RPSP.2020.7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4694: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Clinical trials on drug repositioning for COVID-19 treatment.

    Rosa, Sandro G Viveiros / Santos, Wilson C

    Revista panamericana de salud publica = Pan American journal of public health

    2020  Volume 44, Page(s) e40

    Abstract: The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA ... ...

    Abstract The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus
    Keywords covid19
    Language English
    Publishing date 2020-03-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1376934-0
    ISSN 1680-5348 ; 1020-4989
    ISSN (online) 1680-5348
    ISSN 1020-4989
    DOI 10.26633/RPSP.2020.40
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4694: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Repositioning and investigational drugs for Zika virus infection treatment: a patent review.

    G Viveiros Rosa, Sandro / Fierro, Iolanda M / C Santos, Wilson

    Expert opinion on therapeutic patents

    2020  Volume 30, Issue 11, Page(s) 847–862

    Abstract: Introduction: Zika virus (ZIKV) is transmitted to humans throughout bites of : Areas covered: This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for ... ...

    Abstract Introduction: Zika virus (ZIKV) is transmitted to humans throughout bites of
    Areas covered: This review identifies patent documents on repositioning for ZIKV infection treatment of already approved drugs or phases II/III investigated drugs for other diseases. Thirty-six patents were found reporting compounds with anti-ZIKV activity with application dates ranging from 2015 to 2019.
    Expert opinion: The main drugs claimed in patents were ribavirin, sofosbuvir, and alpha interferons. Preventing CZS is one of the most significant challenges in ZIKV infection. Therefore, repositioning sofosbuvir and niclosamide, that pose no danger for pregnant women, is a particular issue to be considered for clinical tests involving ZIKV disease. Given the substantial costs and developing time of new a drug, repositioning of old drugs is becoming an attractive alternative for diseases with neglected treatments.
    MeSH term(s) Aedes/virology ; Animals ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacology ; Drug Repositioning ; Drugs, Investigational/administration & dosage ; Drugs, Investigational/pharmacology ; Female ; Humans ; Microcephaly/prevention & control ; Microcephaly/virology ; Patents as Topic ; Pregnancy ; Pregnancy Complications, Infectious/drug therapy ; Pregnancy Complications, Infectious/virology ; Zika Virus Infection/complications ; Zika Virus Infection/drug therapy ; Zika Virus Infection/virology
    Chemical Substances Antiviral Agents ; Drugs, Investigational
    Keywords covid19
    Language English
    Publishing date 2020-10-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1186201-4
    ISSN 1744-7674 ; 0962-2594 ; 1354-3776
    ISSN (online) 1744-7674
    ISSN 0962-2594 ; 1354-3776
    DOI 10.1080/13543776.2020.1811854
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3962: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Clinical trials on drug repositioning for COVID-19 treatment

    Sandro G. Viveiros Rosa / Wilson C. Santos

    Revista Panamericana de Salud Pública, Vol 44, Iss 40, Pp 1-

    2020  Volume 7

    Abstract: The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA ... ...

    Abstract The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants’ clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
    Keywords drug repositioning ; clinical trials as topic ; coronavirus infection ; virus diseases ; pneumonia ; viral ; pandemics ; Medicine ; R ; Arctic medicine. Tropical medicine ; RC955-962 ; Public aspects of medicine ; RA1-1270 ; covid19
    Subject code 610
    Language English
    Publishing date 2020-03-01T00:00:00Z
    Publisher Pan American Health Organization
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Vector competence of Culex mosquitoes (Diptera

    Sandro G. Viveiros-Rosa / Eduardo G. Regis / Wilson C. Santos

    Revista Panamericana de Salud Pública, Vol 44, Iss 7, Pp 1-

    Culicidae) in Zika virus transmission: an integrative review

    2020  Volume 9

    Abstract: Objective. To identify studies on the competence of Culex mosquitoes as vectors for the transmission of Zika virus (ZIKV) around the globe. Methods. We performed an integrative review to identify relevant articles on specific experiments to determine ... ...

    Abstract Objective. To identify studies on the competence of Culex mosquitoes as vectors for the transmission of Zika virus (ZIKV) around the globe. Methods. We performed an integrative review to identify relevant articles on specific experiments to determine whether Culex mosquitoes are vectors for ZIKV. The sources we used for our research were the Brazilian Periódicos CAPES electronic portal (MEDLINE/PubMed, ScienceDirect Journals, Nature Publishing Group, SciELO, Springer Link, and 250 other databases) and gray literature. Results. We identified 344 studies, of which 36 were considered for this review. In 8 studies, infection in salivary glands of Culex quinquefasciatus, Culex restuans, Culex tarsalis, and Culex coronator was detected. Cx. quinquefasciatus was the most studied among those confirmed as potential ZIKV vectors, and only strains of Asian lineages (THA/2014/SV0127-14; SZ01 (2016)) and American lineages (BRPE243 (2015); PRVABC59 (2015)) can infect the salivary glands of Culex mosquitoes. The tested African strains (MR766 and DAK AR 41525) were unable to infect salivary glands. Conclusions. There is still a lack of compelling evidence that indicates Culex spp. are a competent ZIKV vector, but they should remain a target for further monitoring studies, especially regarding ZIKV transmission to other species. Furthermore, studies should not be limited to studying whether their salivary glands are infected.
    Keywords public health ; zika virus ; mosquito vectors ; culex ; Medicine ; R ; Arctic medicine. Tropical medicine ; RC955-962 ; Public aspects of medicine ; RA1-1270
    Subject code 001
    Language English
    Publishing date 2020-02-01T00:00:00Z
    Publisher Pan American Health Organization
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top